# Bibliography

> Semaglutide Texas bibliography — The Semaglutide Texas reading list brings together the weight, cardiovascular, kidney, appetite, alcohol and safety papers used in this folio.

The trials and review that give the folio its scale, its time spans and its unresolved questions.

## Weight and duration

[STEP 1](https://pubmed.ncbi.nlm.nih.gov/33567185/) supplies the weight-change comparison. [STEP 5](https://pubmed.ncbi.nlm.nih.gov/36216945/) extends the observation period; [SURMOUNT-5](https://pubmed.ncbi.nlm.nih.gov/40353578/) supplies a direct tirzepatide comparison. They are gathered in the [weight-loss folio](/weight-loss).

## Disease outcomes and treatment burden

[SELECT](https://pubmed.ncbi.nlm.nih.gov/37952131/), [FLOW](https://pubmed.ncbi.nlm.nih.gov/38785209/) and [STEP-HFpEF](https://pubmed.ncbi.nlm.nih.gov/37622681/) ask distinct cardiovascular, kidney and symptom questions. [SUSTAIN-6](https://pubmed.ncbi.nlm.nih.gov/27633186/) and the [safety review](https://pubmed.ncbi.nlm.nih.gov/34305810/) also anchor the side-effects account.

## Appetite and the alcohol experiment

The [rodent neural-pathway study](https://pubmed.ncbi.nlm.nih.gov/32213703/) and the [human alcohol-use-disorder trial](https://pubmed.ncbi.nlm.nih.gov/39937469/) sit together in the [appetite folio](/appetite-and-alcohol). Their different study populations are central to the discussion.

## References

[1] Once-Weekly Semaglutide in Adults with Overweight or Obesity https://pubmed.ncbi.nlm.nih.gov/33567185/
[2] Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial https://pubmed.ncbi.nlm.nih.gov/36216945/
[3] Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes https://pubmed.ncbi.nlm.nih.gov/37952131/
[4] Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes https://pubmed.ncbi.nlm.nih.gov/38785209/
[5] Semaglutide lowers body weight in rodents via distributed neural pathways https://pubmed.ncbi.nlm.nih.gov/32213703/
[6] Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial https://pubmed.ncbi.nlm.nih.gov/39937469/
[7] Safety of Semaglutide https://pubmed.ncbi.nlm.nih.gov/34305810/
[8] Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://pubmed.ncbi.nlm.nih.gov/27633186/
[9] Tirzepatide as Compared with Semaglutide for the Treatment of Obesity https://pubmed.ncbi.nlm.nih.gov/40353578/
[10] Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity https://pubmed.ncbi.nlm.nih.gov/37622681/

---

Semaglutide Texas is my editorial folio of published research; it operates no business and offers no medical advice.